- The MHRA’s Marketing Authorization for SK bioscience COVID-19 vaccine is valid in the United Kingdom.
- SKYCovion™ is the world’s first-ever vaccine developed utilizing the RoseTTAFold, a software tool that uses deep learning.
- SK bioscience has applied for an Emergency Use Listing from the World Health Organization, for enabling equitable access of vaccine in the world.
SEONGNAM, South Korea, May 30, 2023 /PRNewswire/ — SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, has announced today the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorization (MA) for SK bioscience’s COVID-19 vaccine SKYCovion™ (brand name in Korea: SKYCovione™) as a primary series for strong immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. It becomes the 8th COVID-19 vaccine authorized by the UK’s independent medicines regulator. The authorization covers England, Scotland, and Wales.
Click here to read the full article